What to consider when conducting pricing research
Tom Nolte, Director of Business Analytics and Boon Yap, Associate Consultant discuss how to use qualitative research and integrated modelling to optimise price and inform demand forecasts.
Experience conducting research in South East Asia
Our emerging markets team has considerable expertise conducting research in South East Asia, with our Asia headquarters located in Singapore, we can support your market research needs. We have conducted over 150 healthcare market research projects across South East Asia covering a wide variety of research objectives and over 25 therapy areas, for both local and international organisations.
EphMRA Annual Conference 2019
25-27 June 2019 Warsaw, Poland
We are delighted to be sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland 25-27 June. Representing Research Partnership are Director and EphMRA Board Member Richard Head, Director Paula Coyle, and Associate Director Emilie Braund. Also in attendance will be Associate Director An-hwa Lee who sits on the EphMRA Learning and Development Committee, which plans to convene before the conference begins.
Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?
This article, published by Pharma Times May 2019, considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.
The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products in multiple markets. These obstacles partly reflect initial premium pricing of the two available PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab). Price differentials have been all the more marked given the established reliability of low-cost, genericised statins as a tool for lowering cholesterol. In that light, many physicians, thought leaders and payers opted to wait for persuasive outcomes data that would substantiate the ability of the PCSK9 inhibitors to offset higher costs with long-term gains in preventing mortality, hospitalisation or other serious cardiovascular events.
Research Partnership publishes new patient Living with Non-alcoholic Steatohepatitis (NASH) EU report
Living with Non-alcoholic Steatohepatitis (NASH) EU is a study conducted amongst 275 adults with NASH / NAFLD in France, Germany, Italy, Spain and UK. The report consists of 30-minute quantitative online and qualitative telephone interviews with patients. The report, which is now available for purchase, enables pharmaceutical companies developing products in this disease area to gain a deeper understanding of how patients come to be diagnosed with NASH, how it impacts their day-to-day lives and what their attitudes and perceptions are towards the management of their condition.